# Nu Skin account plan

> Nu Skin sells beauty and wellness products through direct selling in nearly 50 markets, plus Rhyz manufacturing: $1,485.2 million 2025 revenue.

## At a glance

Nu Skin Enterprises develops and distributes beauty and wellness products under the Nu Skin, Pharmanex and ageLOC brands in nearly 50 markets, sold by independent Brand Affiliates person-to-person and through social commerce, with a separate store-based model in Mainland China. Alongside the core business, Rhyz owns manufacturing companies that also serve outside customers. 2025 revenue was $1,485.2 million, down 14.3%, and net income was $160.2 million, lifted by a $176.2 million gain on the sale of Mavely. The Utah-based company had about 2,800 employees plus about 5,800 sales employees in Mainland China.

## Business units

- **Americas** (19% of 2025 revenue ($283.0 million)): Canada, Latin America and the United States. North America declined after sales plan changes, while Latin America grew 72.3% to $99.6 million in 2025 under the developing market strategy; Q3 2026 revenue fell 17.0% to $53.1 million.
- **Southeast Asia/Pacific** (14% of 2025 revenue ($209.8 million)): Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Australia, New Zealand and other markets; India pre-market costs are reported here. Revenue fell 14.3% in 2025 and 23.5% in Q3 2026.
- **Mainland China** (13% of 2025 revenue ($195.6 million)): Separate model of retail stores, sales employees, direct sellers and independent marketers, with local manufacturing. Revenue fell 16.9% in 2025 as demand shifted to online marketplaces.
- **Japan** (12% of 2025 revenue ($174.4 million)): Revenue fell 4.0% in 2025 on consumer inflation; Q3 2026 revenue was $38.6 million with a 30.0% contribution margin.
- **Europe & Africa** (10% of 2025 revenue ($150.2 million)): Europe plus South Africa, where sales plan enhancements were introduced from March 2025. Revenue fell 8.5% in 2025 and 26.6% in Q3 2026.
- **South Korea** (9% of 2025 revenue ($130.2 million)): Hit by inflation, political instability and price increases; revenue fell 20.5% in 2025 and Customers fell 28%.
- **Hong Kong/Taiwan** (8% of 2025 revenue ($117.4 million)): Includes Macau; revenue fell 10.1% in 2025 on lower consumer purchasing power, while contribution improved to 31.7% of revenue.
- **Rhyz Manufacturing** (14% of 2025 revenue ($205.8 million)): Elevate Health Sciences (private-label supplements), 3i Solutions, CasePak and Wasatch Product Development. Q3 2026 revenue grew 19.3% to $56.8 million as orders normalized, but its goodwill was impaired by $78.9 million in Q2 2026.
- **Rhyz Other** (1% of 2025 revenue ($17.8 million)): BeautyBio, being wound down in 2026, and LifeDNA (DNA assessment), now wholly owned after buying the remaining 30% for $6.5 million. Mavely was sold in January 2025.

## Strategic priorities

- **Prysm iO intelligent wellness platform**: The device measures skin carotenoids for a Nutritional Health Score; about 41,000 devices were placed and 4.5 million scans run through Q3 2026, and app version 2.0 with AI lifted scan-to-purchase conversion to 10%. Strategy shifted from device placement to an assessment model.
- **Sales channel development**: Compensation plan enhancements, a realigned 2027 incentive roadmap and a new learning platform aim to develop and retain Sales Leaders, whose number fell 13% to 26,995 in Q3 2026.
- **India launch**: Pre-market operations began in Q4 2025 with a digital-first infrastructure through a partnership with Infosys; the formal opening slipped to the first half of 2027, and local manufacturing is a top priority because of high import duties.
- **Operating model and East-West structure**: The organization was realigned into East and West regions led by COO Chayce Clark, using manufacturing hubs in the U.S. and China to improve gross margin and speed to market; core selling expense is targeted around 40%.
- **Women's health anti-aging products**: Anti-aging innovations focused on women's health, previewed at the Nu Skin LIVE convention in Yokohama, will begin rolling out from mid-2027.

## Latest results

In Q3 2026 (quarter to September 30, 2026) revenue fell 14.6% to $311.0 million, with core Nu Skin revenue down 19.2% to $252.6 million and Rhyz Manufacturing up 19.3% to $56.8 million. Customers fell 18% to 609,469 and Sales Leaders 13% to 26,995. Net loss was $(0.7) million; over nine months the net loss was $(248.7) million after a $78.9 million goodwill impairment and a $167.5 million valuation allowance on U.S. deferred tax assets. Guidance for 2026 is revenue of $1.26 to $1.29 billion, down from the February range of $1,350,000,000 to $1,500,000,000, with adjusted EPS of 55 to 65 cents.

## Investments and deals

- **Mavely sale**: The social commerce platform was sold on January 2, 2025 for $230 million in cash and shares, producing a $176.2 million pre-tax gain.
- **Capex for Rhyz plants and IT**: 2026 capex is expected at $40-60 million for Rhyz plant expansion, computer systems and software, and facilities; $30.7 million was spent in the first nine months.
- **New credit agreement**: A $175.0 million term loan and $75.0 million revolver were signed on March 27, 2026; total debt was reduced to $203.7 million.
- **LifeDNA buyout and BeautyBio wind-down**: The remaining 30% of LifeDNA was bought for $6.5 million, while BeautyBio is being wound down.

## Challenges and risks

- **Shrinking sales network**: Customers fell 18%, Paid Affiliates 10% and Sales Leaders 13% in Q3 2026, with the Americas losing 27% of Customers.
- **Weak consumer demand**: Macroeconomic pressure on consumer spending and customer acquisition hit every geographic segment, with Mainland China demand shifting online and inflation weighing on Japan and South Korea.
- **Direct-selling regulation**: Risks include challenges to the network marketing model, limits on sales compensation and Mainland China scrutiny; South Korea commissions were lowered in Q1 2026 to stay compliant with local law.
- **Margin and cash pressure**: Q3 2026 gross margin fell to 65.0% from 70.5% on mix, and nine-month operating cash flow was $(1.4) million vs. +$63.7 million a year earlier.
- **Tariffs and currency**: Tariff uncertainty delayed Rhyz orders in the first half of 2026, and the company is exposed to foreign currency and currency controls.

## What leadership says

> "innovative products alone are not enough to drive sustainable growth" — Ryan Napierski, President and Chief Executive Officer, Q3 2026 earnings call, November 5, 2026

> "Moving manufacturing closer to the customer is expected to improve gross margin, speed to market, and fixed cost optimization" — Ryan Napierski, President and Chief Executive Officer, Q3 2026 earnings call, November 5, 2026

> "2026 represents a pivotal year" — Ryan S. Napierski, President and Chief Executive Officer, Q4 and full-year 2025 earnings call, February 12, 2026


## Where a supplier can help

- **AI and data for Prysm iO**: Tied to the Prysm iO priority: AI recommendation, app analytics and subscription billing partners can help raise the 10% scan-to-purchase conversion.
- **Sales force learning and engagement tools**: Tied to the shrinking sales network and the new learning platform: training content, social selling and CRM tools for affiliates and Sales Leaders.
- **India market entry services**: Tied to the India launch in the first half of 2027: local contract manufacturing, logistics, regulatory and digital commerce providers.
- **Manufacturing capacity for Rhyz and regional hubs**: Tied to Rhyz plant expansion capex and the East-West manufacturing hubs: equipment, packaging and ingredient suppliers.
- **Cost efficiency**: Tied to the margin and cash pressure and the operating model priority: procurement, software consolidation and shared-services providers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1021561/000114036126005130/ef20060638_10k.htm)

Annual report · 2026-02-13

- Nu Skin Enterprises develops and distributes premium beauty and wellness products in nearly 50 markets through direct selling (person-to-person and social commerce); 2025 revenue was $1,485.2 million, down 14.3% from $1,732.1 million (constant currency -13.5%).
- Revenue mix 2025: Beauty $568.1 million (38.3%), Wellness $689.1 million (46.4%), Other (mostly Rhyz external revenue) $228.0 million (15.3%); devices and related consumables were $216 million.
- Nine segments: seven geographic Nu Skin segments (Americas 19% of revenue, Southeast Asia/Pacific 14%, Mainland China 13%, Japan 12%, Europe & Africa 10%, South Korea 9%, Hong Kong/Taiwan 8%) plus Rhyz Manufacturing (14%) and Rhyz Other (1%).
- The sales network is shrinking: Customers fell 10% to 748,796, Paid Affiliates 11% to 129,311 and Sales Leaders 19% to 30,045 at end-2025; Latin America was the bright spot (revenue +72.3% to $99.6 million).
- Net income was $160.2 million (EPS $3.18), lifted by a $176.2 million pre-tax gain on the January 2025 sale of Mavely (sold for $230 million); core Nu Skin gross margin rose 3.1 points to 77.4%.
- 2026 priorities: business model optimization (sales performance plan enhancements), the Prysm iO intelligent wellness device (consumer launch in the back half of 2026, about $30 million of device revenue expected) and a formal India opening in the second half of 2026.
- 2026 capex is expected at about $40-60 million (Rhyz plant expansion, IT systems and software, facilities); debt was cut by $170.0 million to a $225.0 million term loan, and a refinancing of the credit agreement was planned for H1 2026.
- About 2,800 employees plus about 5,800 sales employees in Mainland China; leadership as of February 14, 2026: Steven J. Lund (Executive Chairman), Ryan S. Napierski (President and CEO), James D. Thomas (CFO).
- Key risks: challenges to the network marketing model and direct-selling regulation, Mainland China scrutiny, sales-force retention, tariffs and foreign currency, and adoption risk for Prysm iO among Sales Leaders.

### [Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1021561/000114036126042155/ef20080545_10q.htm)

Interim report · 2026-11-06

- Q3 2026 (quarter to September 30) revenue fell 14.6% to $311.0 million (-13.5% constant currency); nine-month revenue fell 14.6% to $951.7 million.
- Core Nu Skin revenue fell 19.2% to $252.6 million in the quarter, while Rhyz Manufacturing grew 19.3% to $56.8 million as orders normalized.
- Customers fell 18% to 609,469, Paid Affiliates 10% to 116,449 and Sales Leaders 13% to 26,995; the Americas lost 27% of Customers.
- Q3 net loss $(0.7) million (EPS $(0.02)); nine-month net loss $(248.7) million after a $78.9 million goodwill impairment on the manufacturing unit and a $167.5 million valuation allowance on U.S. deferred tax assets.
- Strategy shift: Prysm iO moved from a device placement focus to an assessment model; the India full opening slipped to the first half of 2027; the separate BeautyBio business is being wound down and LifeDNA became wholly owned.
- New $175.0 million term loan and $75.0 million revolver signed March 27, 2026; cash fell to $166.6 million and operations used $1.4 million of cash over nine months.
- G&A fell to $93.9 million in Q3 on lower labor and software costs, partly offset by severance; 2026 capex still expected at $40–60 million.

### [Q3 2026 earnings call transcript](https://www.earningswhispers.com/transcript/NUS/Q32026)

Executive talk · Ryan Napierski, President and Chief Executive Officer · 2026-11-05

- Q3 2026 revenue $311 million and adjusted EPS $0.10, both within guidance; Rhyz manufacturing had "an exceptional quarter" while the core business stayed under pressure.
- Four priorities: advancing the integrated anti-aging platform, strengthening the channel through sales force activation and development, preparing the formal India launch in the first half of 2027, and improving the operating model for profitability.
- Prysm iO: about 41,000 devices placed and 4.5 million scans; app version 2.0 with AI more than doubled scan-to-purchase conversion to 10%; LifePak sales grew nearly 3% year to date.
- Organization realigned around an East-West structure led by COO Chayce Clark, leveraging manufacturing hubs in the U.S. (West) and China (East) to improve gross margin and speed to market.
- Women's health anti-aging innovations previewed at the Nu Skin LIVE convention in Yokohama (about 12,000 sales leaders) will begin rolling out mid-2027.
- Guidance: Q4 revenue $310 to $340 million; 2026 revenue $1.26 to $1.29 billion, reported EPS negative $5.08 to negative $4.98, adjusted EPS 55 to 65 cents; about $5 million of remaining transition costs in Q4.
- Core selling expense targeted around 40%; cash $164.9 million and total debt reduced to $203.7 million.

### [Q4 and full-year 2025 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/02/12/nu-skin-nus-q4-2025-earnings-call-transcript/)

Executive talk · Ryan S. Napierski, President and Chief Executive Officer · 2026-02-12

- Napierski called 2026 "a pivotal year" with three priorities: Prysm iO intelligent wellness, expansion into India and other emerging markets, and operational efficiency.
- Prysm iO measures skin carotenoids to produce a "Nutritional Health Score"; the company holds a database of 21,000,000 scans of more than 10,000,000 people and aimed to place more than 100,000 devices in 2026.
- Prysm iO subscriptions were said to provide more than six times greater customer lifetime value; internal aspiration of 10,000,000 healthy households by 2030.
- India: pre-market operations started mid-November 2025, digital-first infrastructure through a partnership with Infosys, local manufacturing a top priority because of high import duties; formal opening then expected late 2026.
- FY2025 (CFO James Thomas): revenue $1,490,000,000, adjusted EPS $1.27 vs. $0.84, adjusted operating margin 6.7%, core gross margin 77.4%, core selling expense 40.3%.
- 2026 guidance at the time: revenue $1,350,000,000 to $1,500,000,000, EPS $0.80 to $1.20 with a 35% tax rate; growth expected in the second half.
- Other storylines: restaged Tru Face premium skincare line, continued Latin America growth, and improvement sought in China, Japan, Korea and North America.

## Questions about Nu Skin

### What does Nu Skin do?

Nu Skin develops and distributes beauty and wellness products, including devices such as LumiSpa iO and Prysm iO, sold by independent affiliates in nearly 50 markets; its Rhyz arm owns manufacturing companies.

### What is Nu Skin's revenue?

2025 revenue was $1,485.2 million, down 14.3%. Q3 2026 revenue was $311.0 million, and 2026 guidance is $1.26 to $1.29 billion.

### How many employees does Nu Skin have?

About 2,800 full- and part-time employees, excluding about 5,800 sales employees in Mainland China.

### What is Nu Skin's strategy?

Grow wellness through the Prysm iO platform, rebuild the sales channel, open India in the first half of 2027, and run a leaner East-West operating model.

### Who leads Nu Skin?

Ryan S. Napierski is President and CEO, Steven J. Lund is Executive Chairman, and Chayce Clark is COO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
